Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel
September 10, 2024 1:08 PM EDTStifel analyst Alex Thompson raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $40.00 (from $33.00) while maintaining a Buy rating.
The analyst comments "We are increasing our PoS for VRDN-001/003 to 80% from 66% following positive topline data from the Ph3 THRIVE study (Our Take... More
Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
September 10, 2024 11:41 AM EDTBTIG analyst Julian Harrison raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $56.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "15wk THRIVE (active TED Phase 3) data show veligrotug (fka VRDN-001) with at least comparable proptosis efficacy vs. Tepezza at 24wk, and veligrotug's placebo-corrected rates of diplopia resolution and hearing... More
